Perrigo Company plc (PRGO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 27, 2025. Perrigo is a leading pure-play self-care company operating primarily in North America and Europe. The company is currently executing a "Three-S" strategy: Stabilizing Consumer Self-Care Americas, Streamlining the global portfolio, and Strengthening high-growth brands. Key strategic initiatives include the "Supply Chain Reinvention Program" and "Project Energize."
Key Financial Metrics (Nine Months Ended Sept 27, 2025)
| Metric | Value (in millions) |
|---|---|
| Net Sales | $3,143.5 |
| Gross Profit | $1,132.3 |
| Gross Margin | 36.0% |
| Operating Income | $164.9 |
| Operating Margin | 5.2% |
| Net Income (Loss) | $(7.3) |
| Diluted EPS | $(0.05) |
| Cash and Cash Equivalents | $432.1 |
| Total Debt (Long-term + Current) | $3,644.7 |
| Net Cash from Operating Activities | $63.1 |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 2.8% ($91.6 million) year-over-year, driven by prior-year divestitures (Rare Diseases Business, Hospital & Specialty Business) and soft category consumption in Digestive Health and Oral Care. This was partially offset by favorable foreign currency translation ($23.1 million).
- Profitability: Operating income improved significantly to $164.9 million from a loss of $1.3 million in the prior year. This turnaround was driven by a $190.7 million decrease in operating expenses, primarily due to lower restructuring costs, the absence of prior-year impairment charges ($50.3 million), and benefits from Project Energize.
- Segment Performance:
- CSCA (Americas): Operating income increased 8.9% to $203.7 million, aided by infant formula business recovery and cost savings.
- CSCI (International): Operating income surged 109.2% to $136.2 million, largely due to the absence of prior-year impairment charges and lower restructuring costs.
- Divestitures: Completed the sale of the Richard Bittner Business in April 2025 for $14.4 million. Entered a binding agreement to sell the Dermacosmetics Business (expected Q1 2026 closing) for up to €327 million.
Guidance, Outlook, and Risks
- Strategic Reviews: Announced a strategic review of the infant formula business (Nov 5, 2025) to assess alternatives and accelerate cash flows. A review of the Oral Care business is also ongoing.
- Tax Impact: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 is expected to provide a $28.0 million tax benefit in 2025.
- Restructuring: Project Energize is expected to deliver annualized pre-tax savings of $140–$170 million by end of 2026. Supply Chain Reinvention aims for $200–$300 million in annual run-rate savings by 2028.
- Risks:
- Geopolitical: Ongoing conflicts in Ukraine and the Middle East pose supply chain and economic risks.
- Tariffs: New U.S. tariffs are estimated to increase global cost of goods sold by $40–$50 million on a full-year basis.
- Litigation: Significant exposure remains regarding price-fixing lawsuits related to the former Rx business (accrual of $31.0 million) and securities litigation settlements.
- Regulatory: Continued monitoring of FDA requirements for infant formula facilities.
Investor Verification Checklist
- Divestiture Closing: Verify the closing timeline and regulatory approval status for the Dermacosmetics Business sale to Karo Healthcare AB.
- Infant Formula Strategy: Monitor the outcome of the strategic review of the infant formula business and potential asset sales or restructuring.
- Litigation Reserves: Track developments in the generic drug price-fixing MDL and the status of the IRS tax refund litigation regarding omeprazole and ANDA issues.
- Tariff Mitigation: Assess the company's ability to pass on tariff-related cost increases through pricing or supply chain adjustments.
- Debt Covenants: Confirm continued compliance with the 3.00:1.00 net leverage ratio and 3.00:1.00 interest coverage ratio covenants under the Senior Secured Credit Facilities.